Pharmafile Logo

Competition from within

August 25, 2015 | emerging markets 

Published in eyeforpharma July 29 by Rachel Howard

To what extent can Big Pharma expect to face an increasing challenge from globalizing pharmaceutical companies based in emerging markets?

If we take a look at the top 50 pharmaceutical companies of 2013, they are mainly headquartered in North America (18), the EU (18) or Japan (9). Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy – which have since merged – the only representation from the ‘BRIC’ markets (Brazil, Russia, India and China). In ten years’ time, will more ‘home-grown’ emerging market companies feature on this list?

In this article, I will explore and compare the directions the domestic pharmaceutical industries of South Korea, China and Brazil have taken in recent years, and consider what threat, if any, each poses to established pharmaceutical companies on a global scale.

Read the full article here http://www.researchpartnership.com/news/2015/07/competition-from-within/

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Webinar: Uncovering hidden insights into patient compliance

Pharma companies are increasingly looking for ways to provide “beyond the pill" services to support patients with the management of their disease. Adherence tools and programs encourage patients to stay compliant with their treatment...

Webinar: The patient journey: Time to look beyond the physician?

Treatment initiation is a key focus for many pharma companies as part of their strategy to increase script writing and drive greater revenues.

Webinar: Ensuring an actionable segmentation

One of the most consistent issues researchers face with segmentation is ensuring that it is actionable.

Webcast: Leveraging the ASEAN opportunities

Exploring the opportunities for pharma in the ASEAN region and factors to consider when conducting healthcare market research.

Webcast: Biosimilars: Friend or Foe to Healthcare?

Understanding the opportunities for biosimilars and the threats to innovator biologics

Webinar: Understanding the patient journey in China

The Chinese healthcare market is experiencing a period of great change. Utilising local knowledge and detailed case studies, this webinar examines the likely impact on the patient journey and considers...

Webinar: Capturing “in-the-moment” patient and physician insights

Utilising the benefits of mobile technology

Webinar: Observational Research

Presenting a window on the world of your customer

Webinar: The Brazil Conundrum

Conducting research in one of the world's largest pharma markets

Webinar: Demand calibration: What’s inside the black box?

The process of demand calibration of preference share (down-weighting) is often a proprietary "black box" technique, which can mean that the client is unsure how the calibrated figure has been...